News Sentiment

FBIO sentiment intelligence

Fortress Biotech Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors Options RSS feed
Weighted score 59 Balanced news tone 56 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 3.13 Week of 31 Jul 2026
Weighted tone 59/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

75/100 classification confidence.

Company focus 47

directly relevant articles

Source quality 8

high-authority source matches

Trend context Trend inactive

-6.3% over one week, +3.0% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Neutral

Fortress Biotech (FBIO) to Release Earnings on Thursday

Market Reaction

Price moving ahead of tone

67/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 75/100 classification
One-week reaction -6.3% Price reacting lower
Trend fit Trend inactive 3.0% over four weeks
Fair value 26.0% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 20
Neutral 33
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 47
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
TradingKey 7
Market source 7
Seeking Alpha 5
GlobeNewswire 5
TradingView 4
MarketBeat 3
Stock Titan 3
simplywall.st 2

Event Lens

What the news is about

Classified themes
Market update 22
Earnings 21
Regulatory and legal 5
Analyst action 4
Guidance 2
Balance sheet 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-56 of 56
MSN Direct company coverage

Fortress Biotech to Receive $205M as Cyprium Agrees Sale of Rare Pediatric Disease Priority Review Voucher

Fortress Biotech (FBIO) has announced that Cyprium Therapeutics, a company in which Fortress owns a substantial equity stake, has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million. This sale is expected to generate signifi

Tone
Positive 86/100
Event
Deals and strategy
Published
28 Apr 2026 23:39
Source
MSN
GlobeNewswire Direct company coverage

Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights

Fortress Biotech (Nasdaq: FBIO) announced its financial results for the full-year ended December 31, 2025, detailing significant corporate achievements including asset monetizations, regulatory approvals, and advancements in clinical programs. Key highlights include the FDA appro

Tone
Positive 72/100
Event
Earnings
Published
08 Apr 2026 12:39
Source
GlobeNewswire
Stock Titan Direct company coverage

Rare-disease voucher sale brings Fortress more than $100M

Fortress Biotech's subsidiary, Cyprium Therapeutics, has completed the sale of its Rare Pediatric Disease Priority Review Voucher for $205 million. Fortress Biotech anticipates receiving over $100 million from this transaction, which will enhance its financial flexibility for bus

Tone
Positive 91/100
Event
Market update
Published
30 Mar 2026 20:10
Source
Stock Titan
The Manila Times Direct company coverage

Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million

Fortress Biotech's subsidiary, Cyprium Therapeutics, has completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million. Fortress expects to receive over $100 million from the transaction, enhancing its financial flexibility. The PRV was issued fo

Tone
Positive 75/100
Event
Guidance
Published
30 Mar 2026 20:10
Source
The Manila Times
Stocktwits Direct company coverage

FBIO Shares Rally After Unit Sells Priority Review Voucher For $205 Million: Retail Now Pins Hopes On Gene Therapy

Fortress Biotech's shares rallied by 10% after its majority-owned unit, Cyprium Therapeutics, sold a Rare Pediatric Disease Priority Review Voucher for $205 million to Sentynl Therapeutics. The voucher was issued following the FDA approval of ZYCUBO for Menkes disease, and 20% of

Tone
Positive 73/100
Event
Regulatory and legal
Published
23 Feb 2026 17:08
Source
Stocktwits
Timothy Sykes Direct company coverage

Fortress Biotech Inc. Shares Soar After Promising New Developments

Fortress Biotech Inc. (FBIO) shares have risen by 9.97% due to positive market reactions to regulatory approvals, strategic partnerships, and strong revenue growth. The company reported $57.7M in revenue and an impressive 71.6% gross margin, with analysts remaining bullish on its

Tone
Positive 71/100
Event
Earnings
Published
23 Feb 2026 16:45
Source
Timothy Sykes
GlobeNewswire Direct company coverage

UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

Fortress Biotech's majority-owned subsidiary, Cyprium Therapeutics, has announced an agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million. This PRV was issued following the FDA approval of ZYCUBO for Menkes disease, with Sentynl Therapeutics

Tone
Positive 72/100
Event
Regulatory and legal
Published
23 Feb 2026 14:24
Source
GlobeNewswire
Quiver Quantitative Direct company coverage

Fortress Biotech, Inc. and Cyprium Therapeutics Enter Asset Purchase Agreement for $205 Million Rare Pediatric Disease Priority Review Voucher

Fortress Biotech, Inc. and its subsidiary Cyprium Therapeutics have agreed to sell a Rare Pediatric Disease Priority Review Voucher for $205 million. This voucher was obtained after the FDA approved ZYCUBO for Menkes disease, with Sentynl Therapeutics handling its commercializati

Tone
Positive 72/100
Event
Market update
Published
23 Feb 2026 14:08
Source
Quiver Quantitative
RTTNews Direct company coverage

Fortress Biotech's Cyprium To Sell $205 Million Priority Review Voucher; Shares Rise

Fortress Biotech's majority-owned subsidiary, Cyprium Therapeutics, has agreed to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million. This follows the FDA approval of ZUCUBO for Menkes disease. Fortress Biotech (FBIO) shares rose 20% on the news, refle

Tone
Positive 75/100
Event
Regulatory and legal
Published
23 Feb 2026 10:12
Source
RTTNews
MarketBeat Direct company coverage

Fortress Biotech (NASDAQ:FBIO) Shares Cross Above 200-Day Moving Average - Here's What Happened

Fortress Biotech (NASDAQ:FBIO) shares have surpassed their 200-day moving average, trading as high as $3.54 and closing at $3.45 on Wednesday. The company holds a "Moderate Buy" consensus rating from analysts with a target price of $16.50. Wall Street Zen and Zacks recently upgra

Tone
Positive 66/100
Event
Analyst action
Published
19 Feb 2026 09:27
Source
MarketBeat
Stock Traders Daily Direct company coverage

Behavioral Patterns of FBIOP and Institutional Flows

This article analyzes Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (NASDAQ: FBIOP), highlighting weak near and mid-term sentiment but a strong long-term outlook. It presents three AI-generated trading strategies—Position, Momentum Breakout

Tone
Neutral 50/100
Event
Guidance
Published
13 Feb 2026 14:28
Source
Stock Traders Daily
MarketBeat Direct company coverage

Fortress Biotech (NASDAQ:FBIO) Shares Cross Above 200-Day Moving Average - What's Next?

Fortress Biotech (NASDAQ:FBIO) shares have risen above their 200-day moving average, reaching $3.74 on high volume, which is considered a bullish technical signal. The company's fundamentals are mixed, with a market capitalization of $116 million and a negative P/E, but it recent

Tone
Positive 69/100
Event
Market update
Published
11 Feb 2026 07:58
Source
MarketBeat
Aktiencheck Direct company coverage

Fortress Biotech Achieves Landmark FDA Approval for Rare Pediatric Disease Treatment ()

Fortress Biotech and its subsidiary Cyprium Therapeutics received FDA approval for ZYCUBO, the first and only approved treatment for Menkes disease in pediatric patients. This approval, based on compelling clinical data showing significant survival benefits, triggers a Rare Pedia

Tone
Positive 92/100
Event
Regulatory and legal
Published
10 Feb 2026 00:59
Source
Aktiencheck
富途牛牛 Direct company coverage

Fortress Biotech, Inc. (NASDAQ:FBIO) Might Not Be As Mispriced As It Looks After Plunging 28%

Fortress Biotech (NASDAQ:FBIO) shares have dropped 28% in the last month, though they are still up 65% over the past year. Despite a low price-to-sales (P/S) ratio of 1.5x compared to an industry average of 11.5x, its declining revenue and market skepticism about future growth fo

Tone
Neutral 50/100
Event
Earnings
Published
06 Feb 2026 03:28
Source
富途牛牛
Simply Wall Street Direct company coverage

Market Cool On Fortress Biotech, Inc.'s (NASDAQ:FBIO) Revenues Pushing Shares 28% Lower

Fortress Biotech's shares have fallen 28% in the last month, though they are still up 65% over the year. The company's price-to-sales (P/S) ratio of 1.5x is considerably lower than the industry average, largely due to a 24% decline in revenue last year. Despite analyst forecasts

Tone
Negative 33/100
Event
Earnings
Published
06 Feb 2026 02:29
Source
Simply Wall Street